Experiments analgesics

OxyContin is a controlled-released form of oxycodone and indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time OxyContin is not intended for use as a PRN analgesic The patient may experience fewer adverse reactions with oxycodone tlian morphine, and the drug is effective and safe for the elderly. The tablets are to be swallowed whole and are not to be broken, chewed, or crushed. 

The three prototype mixed p agonist/S antagonists described in this chapter have excellent potential as analgesics with low propensity to produce tolerance and dependence. The pseudotetrapeptide DIPP-NH2[ ] has already been shown to produce a potent analgesic effect, less tolerance than morphine, and no physical dependence upon chronic administration. In preliminary experiments, the tetrapeptides DIPP-NH2 and DIPP-NH2[T] were shown to cross the BBB to some extent, but further structural modifications need to be performed in order to improve the BBB penetration of these compounds. The Tyr-Tic dipeptide derivatives can also be expected to penetrate into the central nervous system because they are relatively small, lipophilic molecules. In this context, it is of interest to point out that the structurally related dipeptide H-Dmt-D-Ala-NH-(CH2)3-Ph (SC-39566), a plain p-opioid agonist, produced antinociception in the rat by subcutaneous and oral administration [72], As indicated by the results of the NMR and molecular mechanics studies, the conformation of the cyclic p-casomorphin analogue H-Tyr-c[-D-Orn-2-Nal-D-Pro-Gly-] is stabilized by intramolecular hydrogen bonds. There-... 

When the placebo cream had not been applied, the researchers found activation in areas of the brain that they identified as the pain matrix . But when the same pain stimuli were administered with the placebo cream, activation in these pain-responsive regions of the brain was reduced, and the more pain relief the subjects reported, the greater the reduction of activation in the pain matrix. This told Wager that people actually do experience less pain when given placebo analgesics, and this change in experience is accompanied by changes in brain activity. 

Low-dose opioid analgesics (e.g., oxycodone) may be useful for patients who experience no relief with acetaminophen, NSAIDs, intraarticular injections, or topical therapy. 

Ketamine has analgesic activity that persists beyond the period of unconsciousness up to 1 h after injection. On regaining consciousness, the patient may experience a disconnection between outside reality and inner mental state (dissociative anesthesia). Frequently there is memory loss for the duration of the recovery period however, adults in particular complain about dis-Ltillmann, Color Atlas of Pharmacology... 

Briggs D, Calder I, Woods R, Tange J The influence of metabolic variation on analgesic nephrotoxicity. Experiments with the Gunn rat. Pathology 14 349, 1982... 

If signs of excessive opioid-related adverse experiences are observed, the next dose may be reduced. If this adjustment leads to inadequate analgesia, a supplemental dose of IR oxycodone may be given. Alternatively, nonopioid analgesic adjuvants may be employed. Make dose adjustments to obtain an appropriate balance between pain relief and opioid-related adverse experiences. 

Patients dependent on narcotics Patients dependent on narcotics may experience withdrawal symptoms upon the administration of nalbuphine. If unduly troublesome, control by slow IV administration of small increments of morphine until relief occurs. If the previous analgesic was morphine, meperidine, codeine or another narcotic... 

Some patients undergoing long-term opioid treatment develop a tolerance with loss of analgesic efficacy. The mechanisms behind this effect are likely to be multi-faceted and partly determined by individual factors. There is widespread and documented experience that the tolerance developed in a particular individual is not developed in parallel for different opioids. Different sources therefore recommend... 

Pain consists of both sensory and affective (emotional) components. Opioid analgesics are unique in that they can reduce both aspects of the pain experience, especially the affective aspect. In contrast, nonsteroidal anti-inflammatory analgesic drugs have no significant effect on the emotional aspects of pain. 

For a patient in severe pain, the administration of an opioid analgesic is usually considered a primary part of the overall management plan. Determining the route of administration (oral, parenteral, neuraxial), duration of drug action, ceiling effect (maximal intrinsic activity), duration of therapy, potential for adverse effects, and the patient s past experience with opioids all should be addressed. One of the principal errors made by physicians in this setting is failure to adequately assess a patient s pain and to match its severity with an appropriate level of therapy. Just as important is the principle that following delivery of the therapeutic plan, its effectiveness must be reevaluated and the plan modified, if necessary, if the response was excessive or inadequate. 

The euphoria, indifference to stimuli, and sedation usually caused by the opioid analgesics, especially when injected intravenously, tend to promote their compulsive use. In addition, the addict experiences abdominal effects that have been likened to an intense sexual orgasm. These factors constitute the primary reasons for opioid abuse liability and are strongly reinforced by the development of physical dependence. This disorder has been linked to dysregulation of brain regions mediating reward and stress (see Chapter 32). 

---